Proteomic study of plasma from moderate hypercholesterolemic patients

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Moderate hypercholesterolemia poses significant cardiovascular risks.
• Statins, like simvastatin, are widely used to manage hypercholesterolemia.
• Understanding the molecular mechanisms of statin action is crucial for optimizing treatment.

Purpose of the Study:

• To investigate the impact of simvastatin treatment on plasma protein expression in hypercholesterolemic patients.
• To identify specific protein isoforms affected by simvastatin using proteomics.
• To correlate proteomic changes with plasma cholesterol levels.

Main Methods:

• Proteomic analysis using two-dimensional electrophoresis and mass spectrometry.
• Comparison of plasma protein profiles before and after 12 weeks of simvastatin treatment (40 mg/day).
• Inclusion of a control group (CR) with similar cardiovascular risk factors.

Main Results:

• Hypercholesterolemic patients showed altered expression of fibrinogen gamma (FGG) and beta (FGB) chains, apolipoprotein A-IV, and haptoglobin compared to controls.
• Simvastatin treatment modulated the expression of specific isoforms of FGG, FGB, vitamin D binding protein, apo A-IV, and haptoglobin.
• Changes in FGG isoform 1 and FGB isoforms 1 and 2 were positively correlated with total plasma cholesterol levels.

Conclusions:

• Proteomic analysis reveals significant alterations in plasma protein profiles due to simvastatin treatment in hypercholesterolemic patients.
• Simvastatin influences key proteins involved in hemostasis and lipid metabolism.
• Plasma proteomics offers a valuable tool for elucidating the molecular mechanisms underlying simvastatin's effects.